PEDIATRICS Vol. 108 No. 2 August 2001, p. e24

ELECTRONIC ARTICLE:
Cost-Effectiveness Analysis of an Intranasal Influenza Vaccine for the Prevention of Influenza in Healthy Children

Received Jan 5, 2001; accepted Mar 26, 2001.

Bryan R. Luce^*, Kenneth M. Zangwill, Cynthia S. Palmer^*, Paul M. Mendelman^§, Lihan Yan, Mark C. Wolff, Iksung Cho^§, S. Michael Marcy^{, ¶}, Dominick Iacuzio^#, and Robert B. Belshe^**

From ^* MEDTAP International, Bethesda, Maryland;  UCLA Center for Vaccine Research, Torrance, California; ^§ Aviron, Mountain View, California;  EMMES Corporation, Potomac, Maryland; ^¶ Southern California Kaiser Permanente Health Care Program, Panorama City, California; ^# National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland; and ^** St Louis University Health Science Center, St Louis, Missouri.

Objective.  Intranasal influenza vaccine has proven clinical efficacy and may be better tolerated by young children and their families than an injectable vaccine. This study determined the potential cost-effectiveness (CE) of an intranasal influenza vaccine among healthy children.

Methods.  We conducted a CE analysis of data collected between 1996 and 1998 during a prospective 2-year efficacy trial of intranasal influenza vaccine, supplemented with data from the literature. The CE analysis included both direct and indirect costs. We enrolled 1602 healthy children aged 15 to 71 months in year 1, 1358 of whom were enrolled in year 2. One or 2 doses of intranasal influenza vaccine or placebo were administered to measure the cost per febrile influenza-like illness (ILI) day avoided.

Results.  During the 2-year study period, vaccinated children had an average of 1.2 fewer ILI fever days/child than unvaccinated children. In an individual-based vaccine delivery scenario with vaccine given twice in the first year and once each year thereafter at an assumed base case total cost of $20 for the vaccine and its administration (ie, per dose), CE was approximately $30/febrile ILI day avoided. CE ranged from $10 to $69/febrile ILI day avoided at $10 to $40/dose, respectively. In a group-based delivery scenario, vaccination was cost saving compared with placebo and remained so if vaccine cost was <$28 (the break-even price per dose). In the individual-based scenario, vaccination was cost saving if vaccine cost was <$5. In this scenario, nearly half of lost productivity in the vaccine group was attributable to vaccine visits, which overshadowed the relatively modest savings in ILI-associated costs averted.

Conclusions.  Routine use of intranasal influenza vaccine among healthy children may be cost-effective and may be maximized by using group-based vaccination approaches. cost-effectiveness, influenza, vaccine, children. .

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. W McCarthy and D. R Kockler Trivalent Intranasal Influenza Vaccine, Live Ann. Pharmacother., December 1, 2004; 38(12): 2086 - 2093. [Abstract] [Full Text] [PDF]

				B. Schwartz An intranasal influenza vaccine for the prevention of influenza in healthy children was cost effective Evid. Based Med., March 1, 2002; 7(2): 63 - 63. [Full Text] [PDF]